| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Radiotherapy and Radiobiology [E. S., W. S.], Department of Clinical Pharmacology, Section of Experimental Oncology and Molecular Pharmacology [V. W., T. L., B. J.], Department of Dermatology, Division of General Dermatology [T. L., E. H-R., H. P., B. J.], Department of Internal Medicine I, Division of Hematology and Hemostaseology [P. V.], Department of Clinical Pathology [F. W.], Ludwig Boltzmann Institute for Clinical and Experimental Oncology [H. P.], and Center of Excellence for Clinical and Experimental Oncology, [E. S., H. P.], University Hospital Vienna, 1090 Vienna, Austria; Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 [M. W., K. N. W., D. F.]; and Department of Medical Oncology, Washington University, St. Louis, Missouri 63110 [K. N. W.]
The microphthalmia transcription factor MITF plays a pivotal role in the development and differentiation of melanocytes. The purpose of this work was to investigate the expression and function of the melanocyte-specific isoform MITF-M in human melanoma. We found that MITF-M is repressed in 8 of 14 established melanoma cell lines tested. Transfection of MITF-M into a melanoma cell line (518A2) lacking the M-isoform and into a permanent cell line established from normal melanocytes (NMel-II) resulted in slower tumor growth in a severe combined immunodeficient-mouse xenotransplantation model. The growth difference between vector control-transfected tumors derived from the NMel-II cell line (mean tumor weight ± SD, 3.2 g ± 1.13) and MITF-M (+) transfectants (mean tumor weight ± SD, 1.1 g ± 0.49) was significant (P = 0.018). The mean tumor weight of control-transfected 518A2 tumors was 0.99 g ± 0.22 and of MITF-M (+) transfectants, 0.69 g ± 0.32. The difference in growth between 518A2 controls and the MITF-M (+) transfectants was clear, however it did not reach statistical significance (P = 0.08). In addition to the growth-inhibitory effects, MITF-M expression led to a change in the histopathological appearance of tumors from epitheloid toward a spindle-cell type in vivo. These results indicate a role for the MITF-M isoform in the in vivo growth control and the phenotype of human melanoma. In conclusion, MITF-M may qualify as a marker capable of identifying subgroups of melanoma patients with different tumor biology and prognosis.
This article has been cited by other articles:
![]() |
M. F. Segura, D. Hanniford, S. Menendez, L. Reavie, X. Zou, S. Alvarez-Diaz, J. Zakrzewski, E. Blochin, A. Rose, D. Bogunovic, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor PNAS, February 10, 2009; 106(6): 1814 - 1819. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. van Gils, E. M. Lodder, H. W. Mensink, E. Kilic, N. C. Naus, H. T. Bruggenwirth, W. van IJcken, D. Paridaens, G. P. Luyten, and A. de Klein Gene Expression Profiling in Uveal Melanoma: Two Regions on 3p Related to Prognosis Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4254 - 4262. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ugurel, R. Houben, D. Schrama, H. Voigt, M. Zapatka, D. Schadendorf, E. B. Brocker, and J. C. Becker Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response Clin. Cancer Res., November 1, 2007; 13(21): 6344 - 6350. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Stecca, C. Mas, V. Clement, M. Zbinden, R. Correa, V. Piguet, F. Beermann, and A. Ruiz i Altaba Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways PNAS, April 3, 2007; 104(14): 5895 - 5900. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Carreira, J. Goodall, L. Denat, M. Rodriguez, P. Nuciforo, K. S. Hoek, A. Testori, L. Larue, and C. R. Goding Mitf regulation of Dia1 controls melanoma proliferation and invasiveness Genes & Dev., December 15, 2006; 20(24): 3426 - 3439. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schepsky, K. Bruser, G. J. Gunnarsson, J. Goodall, J. H. Hallsson, C. R. Goding, E. Steingrimsson, and A. Hecht The Microphthalmia-Associated Transcription Factor Mitf Interacts with {beta}-Catenin To Determine Target Gene Expression Mol. Cell. Biol., December 1, 2006; 26(23): 8914 - 8927. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, C. Kuo, H.-J. Wang, R. Milford, D. L. Morton, et al. Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients Clin. Cancer Res., February 15, 2006; 12(4): 1137 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Larribere, C. Hilmi, M. Khaled, C. Gaggioli, K. Bille, P. Auberger, J. P. Ortonne, R. Ballotti, and C. Bertolotto The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis Genes & Dev., September 1, 2005; 19(17): 1980 - 1985. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wellbrock and R. Marais Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation J. Cell Biol., August 29, 2005; 170(5): 703 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Busca, E. Berra, C. Gaggioli, M. Khaled, K. Bille, B. Marchetti, R. Thyss, G. Fitsialos, L. Larribere, C. Bertolotto, et al. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells J. Cell Biol., July 4, 2005; 170(1): 49 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Miller, J. Du, S. Rowan, C. L. Hershey, H. R. Widlund, and D. E. Fisher Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma Cancer Res., January 15, 2004; 64(2): 509 - 516. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Kuiper, M. Schepens, J. Thijssen, M. van Asseldonk, E. van den Berg, J. Bridge, E. Schuuring, E. F.P.M. Schoenmakers, and A. G. van Kessel Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution Hum. Mol. Genet., July 15, 2003; 12(14): 1661 - 1669. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Du, A. J. Miller, H. R. Widlund, M. A. Horstmann, S. Ramaswamy, and D. E. Fisher MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma Am. J. Pathol., July 1, 2003; 163(1): 333 - 343. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |